A Secret Partner Joins the High-Stakes Quest for a Diabetes Cure

LAS VEGAS – July 21, 2026 – In the high-stakes world of biotechnology, progress often hinges on assembling the right pieces of a complex puzzle. Today, emerging biotech firm Avaí Bio announced it has found a crucial piece for its ambitious diabetes therapy. Through its joint venture, Insulinova, the company has secured an agreement with an unnamed but “premier, internationally acclaimed partner” to supply the very engine of its potential cure: insulin-producing cells.

The announcement represents a significant milestone for Insulinova, a 50/50 joint venture between Las Vegas-based Avaí Bio and the Singaporean cell-encapsulation specialist Austrianova. Formed in late 2025, the venture aims to develop a therapy that could liberate millions of people from the daily regimen of insulin injections. While the partner’s identity remains under wraps pending the finalization of definitive agreements, the collaboration injects a powerful dose of validation and capability into a project targeting one of the world’s most pervasive chronic diseases.

A Three-Pillar Strategy to Remake Insulin

The Insulinova therapy is not a single invention but a sophisticated integration of three distinct pillars of innovation. Today’s agreement secures the first and most fundamental pillar: a reliable, scalable source of high-quality, programmed cells that can produce insulin.

“Securing a world-class partner to supply the insulin-producing cells is a critical step in advancing the Insulinova program,” said Chris Winter, CEO of Avaí Bio, in a statement. The cells are the biological engine, designed to function like the body’s own pancreatic islet cells, which are destroyed or dysfunctional in people with type 1 and severe type 2 diabetes.

The second pillar is Austrianova’s proprietary Cell-in-a-Box® technology, a protective shield designed to solve the central challenge of cell therapy: immune rejection. The technology encases the therapeutic cells in a semi-permeable, porous capsule. These capsules, roughly the size of a pinhead, allow vital nutrients and oxygen to flow in and, crucially, allow the insulin produced by the cells to flow out. At the same time, they form a physical barrier that hides the implanted cells from the patient’s immune system, potentially eliminating the need for the harsh, lifelong immunosuppressant drugs required by competing therapies.

“Our team has spent many years developing and validating the Cell-in-a-Box® technology,” noted Dr. Brian Salmons, CEO of Austrianova. “Clinical studies have demonstrated that encapsulated cells can survive for extended periods following implantation.” Preclinical data has already shown that the technology, when used with porcine islet cells in diabetic animal models, can maintain normal blood sugar levels for over six months.

The third pillar is the strategic and financial framework provided by Avaí Bio. According to SEC filings from the venture’s formation, Avaí committed up to $1.5 million in initial capital to get Insulinova off the ground. Its business model is built on identifying promising technologies and assembling them through licensing and joint ventures, acting as a strategic integrator in a field often defined by siloed research. This latest agreement is the clearest execution of that strategy to date.

Navigating a Crowded and Competitive Field

Insulinova enters a fiercely competitive but potentially massive market. The diabetes cell therapy space, valued at around $50 million in 2025, is projected by some analysts to explode to over $4 billion by 2035. This growth is attracting a host of well-funded and scientifically advanced competitors.

The current leader is arguably Vertex Pharmaceuticals, whose investigational therapy, zimislecel (VX-880), has already enabled some clinical trial participants to achieve insulin independence. However, VX-880 requires patients to take chronic immunosuppressants. Vertex is now developing a follow-up, VX-264, that incorporates its own encapsulation device to bypass this requirement, validating the core approach that Insulinova is pursuing with Cell-in-a-Box®.

Other players like Sernova Corp. are developing implantable devices like the Cell Pouch System to create a friendly, vascularized home for transplanted cells, while Kriya Therapeutics is pioneering a gene therapy approach to coax muscle cells into regulating blood sugar. Even as these futuristic therapies advance, the landscape is also being reshaped by more immediate innovations, including new oral GLP-1 drugs, once-weekly insulin formulations, and automated insulin delivery systems like Beta Bionics' iLet Bionic Pancreas.

Against this backdrop, Insulinova’s three-part strategy appears carefully constructed. By partnering for the cells, leveraging Austrianova’s proven encapsulation tech, and focusing its own resources on integration and clinical advancement, the venture is taking a pragmatic approach to a complex problem. The goal is to create a “functional cure” that is not only effective but safe and scalable enough to become a mainstream alternative to lifelong disease management.

The Signal in the Secrecy

The decision to keep the new partner’s name confidential for now is more than just a footnote; it is a signal of the deal's strategic importance. In biotech, such secrecy often precedes the finalization of complex intellectual property rights, supply terms, and co-development responsibilities. It allows the partners to align completely before facing the intense scrutiny of the market and competitors.

For Avaí Bio, a company traded on the OTCQB market, securing a partner described as “premier” and “internationally acclaimed” is a transformative event. It provides external validation from an established leader, significantly de-risking the technical and scientific pathway. It suggests that Insulinova’s combination of technologies was compelling enough to attract a top-tier player, lending immense credibility to the entire enterprise as it seeks to secure further funding for costly clinical trials.

This move is the linchpin that connects the lab to the future clinic. Without a consistent and high-quality source of insulin-producing cells, the Cell-in-a-Box® technology is just a sophisticated container. With this partnership, the two core components of the therapy are now aligned, allowing Insulinova to shift its focus toward the long and rigorous process of preclinical and clinical testing.

While today’s announcement does not name the partner, it clearly names the ambition. The key components are now in place, and the next phase of the journey—proving the combination works safely and effectively in humans—can begin in earnest. The agreement may have been negotiated behind closed doors, but its implications send a clear signal that the race to develop a functional cure for diabetes has a newly strengthened contender.